TY - JOUR
T1 - Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin
AU - Hatziioannou, Theodora
AU - Delahaye, Edwige
AU - Martin, Fransisco
AU - Russell, Stephen J.
AU - Cosset, François Loïc
PY - 1999/6/10
Y1 - 1999/6/10
N2 - We have previously shown that retroviral vector particles derived from Moloney murine leukemia virus (MoMuLV) can efficiently incorporate influenza hemagglutinin (HA) glycoproteins from fowl plague virus (FPV), thus conferring a broad tropism to the vectors. To modify its host range, we have engineered the FPV HA to display four different polypeptides on its N terminus: the epidermal growth factor, an anti-human MHC class I molecules scFv (single-chain antibody), an anti-melanoma antigen scFv, and an IgG Fc- binding polypeptide. All recombinant HA glycoproteins were correctly expressed and processed, and efficiently incorporated into Mo-MuLV retroviral particles, indicating that amino-terminal insertion of large polypeptides did not alter the conformation of HA chimeras. Virions carrying the different chimeras bound specifically to cells expressing the targeted cell surface molecules of each ligand. In addition, all virion types were infectious but exhibited various degrees of specificity regarding the use of the targeted cell surface molecule versus the wild-type FPV HA receptor for cell entry and infection. For some ligands tested, infectivity was significantly increased on cells that express the targeted receptor, compared with cells that express only the wild-type HA receptor. Furthermore, some polypeptides could abolish infectivity via the wild-type FPV HA receptor. Our data therefore indicate that it is possible to engineer the HA envelope glycoprotein by fusing ligands to its amino-terminal end without affecting its fusion activity.
AB - We have previously shown that retroviral vector particles derived from Moloney murine leukemia virus (MoMuLV) can efficiently incorporate influenza hemagglutinin (HA) glycoproteins from fowl plague virus (FPV), thus conferring a broad tropism to the vectors. To modify its host range, we have engineered the FPV HA to display four different polypeptides on its N terminus: the epidermal growth factor, an anti-human MHC class I molecules scFv (single-chain antibody), an anti-melanoma antigen scFv, and an IgG Fc- binding polypeptide. All recombinant HA glycoproteins were correctly expressed and processed, and efficiently incorporated into Mo-MuLV retroviral particles, indicating that amino-terminal insertion of large polypeptides did not alter the conformation of HA chimeras. Virions carrying the different chimeras bound specifically to cells expressing the targeted cell surface molecules of each ligand. In addition, all virion types were infectious but exhibited various degrees of specificity regarding the use of the targeted cell surface molecule versus the wild-type FPV HA receptor for cell entry and infection. For some ligands tested, infectivity was significantly increased on cells that express the targeted receptor, compared with cells that express only the wild-type HA receptor. Furthermore, some polypeptides could abolish infectivity via the wild-type FPV HA receptor. Our data therefore indicate that it is possible to engineer the HA envelope glycoprotein by fusing ligands to its amino-terminal end without affecting its fusion activity.
UR - http://www.scopus.com/inward/record.url?scp=0033542387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033542387&partnerID=8YFLogxK
U2 - 10.1089/10430349950017860
DO - 10.1089/10430349950017860
M3 - Article
C2 - 10395378
AN - SCOPUS:0033542387
SN - 1043-0342
VL - 10
SP - 1533
EP - 1544
JO - Human gene therapy
JF - Human gene therapy
IS - 9
ER -